Cargando…
Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes
RATIONALE: Elexacaftor, tezacaftor, and ivacaftor (ETI) in triple combination improves pulmonary health for people with cystic fibrosis (PwCF). However, its impact on objective measures of sinus disease and health utility is unestablished. OBJECTIVES: To evaluate the impact of ETI on chronic rhinosi...
Autores principales: | Beswick, Daniel M., Humphries, Stephen M., Balkissoon, Connor D., Strand, Matthew, Vladar, Eszter K., Lynch, David A., Taylor-Cousar, Jennifer L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787790/ https://www.ncbi.nlm.nih.gov/pubmed/34436985 http://dx.doi.org/10.1513/AnnalsATS.202101-057OC |
Ejemplares similares
-
Objective and patient‐based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy
por: Beswick, Daniel M., et al.
Publicado: (2022) -
Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del
por: Beswick, Daniel M., et al.
Publicado: (2022) -
Glycosylation and the cystic fibrosis transmembrane conductance regulator
por: Scanlin, Thomas F, et al.
Publicado: (2001) -
Where Is the Cystic Fibrosis Transmembrane Conductance Regulator?
por: Barbry, Pascal, et al.
Publicado: (2021) -
Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives
por: Schmidt, Béla Z, et al.
Publicado: (2016)